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Quality of lifeAbstract Background: Health-related quality of life (HRQoL) enhances understanding of
treatment effects that impact clinical decision-making. Although the primary end-point was
not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established etir-
inotecan pegol, a long-acting topoisomerase-1 (TOP1) inhibitor, as a promising therapeutic
for patients with advanced/metastatic breast cancer (MBC) achieving clinically meaningful
benefits in median overall survival (OS) for patients with stable brain metastases, with liver
metastases or  2 sites of metastatic disease compared to treatment of physician’s choice
(TPC). Reported herein are the findings from the preplanned secondary end-point of HRQoL.
Patients and methods: HRQoL, assessed by European Organisation for Research and Treat-
ment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) (version 3.0)
supplemented by the breast cancer-specific Quality of Life Questionnaire (QLQ-BR23), was
evaluated post randomisation in 733 of 852 patients with either anthracycline-, taxane- and
capecitabine-pretreated locally recurrent or MBC randomised to etirinotecan pegol
(nZ 378; 145 mg/m2 every 3 weeks (q3wk)) or single-agent TPC (nZ 355). Patients completed
assessments at screening, every 8 weeks (q8wk) during treatment, and end-of-treatment.
Changes from baseline were analysed, and the proportions of patients achieving differences
(5 points) in HRQoL scores were compared.
Results: Differences were seen favouring etirinotecan pegol up to 32 weeks for global health sta-
tus (GHS) and physical functioning scales (P < 0.02); numerical improvement was reported in
other functional scales. The findings from HRQoL symptom scales were consistent with adverse
event profiles; etirinotecan pegol was associated with worsening gastrointestinal symptoms
whereas TPC was associated with worsened dyspnoea and other systemic side-effects. Analysis
of GHS and physical functioning at disease progression showed a decline in HRQoL in both
treatment arms, with a mean change from baseline of 9.4 and 10.8 points, respectively.
Conclusion: There was evidence of benefit associated with etirinotecan pegol compared with cur-
rent standard of care agents in multiple HRQoL measurements, including global health status
and physical functioning, despite worse gastrointestinal symptoms (e.g. diarrhoea). Patients in
both arms had a decline in HRQoL at disease progression.
Study number: NCT01492101.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
While there are different treatment approaches for
women with advanced/metastatic breast cancer (MBC)
depending on the molecular phenotype, chemotherapy
remains fundamental to the management of most pa-
tients. With advances in the treatment of MBC, more
women are living longer with their disease [1e3].
Nevertheless, the treatment of MBC remains essentially
palliative rather than curative, with more than 500,000
women dying annually from the disease worldwide
[4e5]. The median survival of patients with MBC is
approximately 24 months, but varies widely between
prognostic subgroups [6e10].
The key aims in treating women with MBC are to
prolong survival and maintain or improve QoL. As the
focus of treatment is primarily palliative, the impact of
both the disease and its treatment on patients’ functional
abilities has led to the incorporation of patient-reported
clinical outcome (PRO) measures into clinical trials [11].
Health-related quality of life (HRQoL) incorporates
domains related to physical, mental, emotional, and so-
cial functioning that go beyond the direct measures ofhealth and focusses on the QoL consequences of health
status [12]. Increasing evidence shows that overall out-
comes for patients with MBC improve when therapy is
not just focussed on the disease but also on minimising
disease-related and treatment-related symptoms [13].
Despite PRO measures rarely being used for drug
approval, the effect of an intervention on HRQoL is
significant for both patients and clinicians [14e15].
The international phase III BEACON (BrEAst
Cancer Outcomes with NKTR-102) trial randomly
assigned patients with heavily pre-treated MBC either to
etirinotecan pegol (NKTR-102), or to single agent
treatment of physician’s choice (TPC) comprising spe-
cific cytotoxics commonly used in this setting [16].
Etirinotecan pegol is a novel, long-acting polymer-
engineered pegylated topoisomerase-1 (TOP1) inhibitor
designed to provide continuous exposure to SN38, the
active moiety of irinotecan, at the site of the tumour
through altered pharmacokinetics and exploitation of
the enhanced permeability and retention (EPR) effect
[17]. Preclinical experiments and initial clinical studies
have demonstrated a marked contrast in the pharma-
cokinetic profile of SN38 after treatment with
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lated to enhanced antitumour activity and improved
tolerability, namely reduced and delayed myelosup-
pression and gastrointestinal toxicities [17e20]. The
primary end-point of BEACON was not achieved;
nevertheless, overall survival (OS) did numerically
favour etirinotecan pegol, although this did not achieve
statistical significance [16]. The comparison of HRQoL
outcomes was a planned secondary outcome of the trial;
it was hypothesised that HRQoL would improve in
patients treated with etirinotecan pegol compared to
those in the TPC control arm.2. Methods
2.1. Patients and study design
From December 2011 to August 2013, the open-label,
randomised, multi-centre BEACON trial enrolled 852
women with locally recurrent or MBC who had previ-
ously received an anthracycline (unless contraindicated
or not medically appropriate), a taxane and capecita-
bine. Patients had to have an Eastern Cooperative
Oncology Group (ECOG) performance status of 0e1
and have received a minimum of two prior cytotoxic
regimens for advanced disease with the last dose of
chemotherapy within 6 months of randomisation and
no more than five prior cytotoxic regimens for breast
cancer in all settings. Patients with stable brain metas-
tases (symptomatically and on imaging) were eligible,
provided local therapy (surgery, whole brain or stereo-
tactic radiation) had been completed and corticosteroids
for this indication had been discontinued at least 3
weeks before randomisation. The study was conducted
at 139 community and academic centres, worldwide
including in North America, Europe and the Republic
of Korea; nearly half the patients were enrolled in North
America.
Patients were randomly assigned via a central ran-
domisation system in a 1:1 ratio to etirinotecan pegol
(145 mg/m2 once every 21 d as a 90-min intravenous (i.v.)
infusion on day 1 of each treatment cycle) or single-agent
TPC (eribulin, ixabepilone, vinorelbine, gemcitabine,
paclitaxel, docetaxel or nab-paclitaxel) administered ac-
cording to local practice or in accordance with local
product labelling. Prior to randomisation, the Investi-
gator established and centrally registered as part of the
informed consent process, the TPC that would be offered
to the patient. Treatment continued until disease pro-
gression, the development of unacceptable toxicity or
withdrawal of patient consent. Dose delays, reductions
and discontinuations were defined for etirinotecan pegol
but made according to the prescribing information or
local practice guidelines pertaining to TPC.
The trial was conducted under the principles of the
International Conference on Harmonisation GoodClinical Practice standards and in accordance with the
Declaration of Helsinki, U.S. Food and Drug Admin-
istration regulations and all other applicable regula-
tions. All patients provided written informed consent
prior to any study-related procedures. Approval was
obtained from the relevant institutional review board
(IRB) or independent ethics committee (IEC) at each
site. The study is registered on ClinicalTrials.gov
(NCT01492101).
2.2. HRQoL assessment
HRQoL was evaluated using two validated question-
naires designed to assess both disease-related symptoms
and the side-effects of treatment as well as their impact
on everyday life, namely the European Organisation for
Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC QLQ-C30) and its
associated breast cancer-specific QoL questionnaire, the
EORTC QLQ-BR23 (BR23). All patients were eligible
for HRQoL assessment. Questionnaires were completed
at Screening, Cycle 1 (baseline at the start of the study
treatment) then every 8 weeks (7 d) prior to radio-
logical tumour assessment while on study treatment and
at the End-of-Treatment visit (within 30 d  7 d from
last dose of study treatment). At the discretion of the
investigator, earlier radiological assessment could be
made if progression was suspected clinically, in which
case the patient would be asked to complete a HRQoL
questionnaire (EORTC QLQ-C30 with BR23 subscale)
prior to that radiological assessment. Safety was
assessed in all patients who received at least one dose of
assigned treatment. Adverse events (AEs) were assessed
from the first dose of treatment until 30 d after the last
dose, and were classified and graded according to the
National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
The EORTC QLQ-C30 questionnaire is a 30-item,
cancer-specific, multi-dimensional self-administered
questionnaire that has been validated in cross-cultural
settings [21]. It comprises five multi-item functional
scales (physical functioning, role functioning, emotional
functioning, cognitive functioning and social func-
tioning); a two-item Global Health Status (GHS) scale;
and nine symptom scales and items (fatigue, nausea/
vomiting, pain, dyspnoea, insomnia, appetite loss, con-
stipation, diarrhoea, and financial difficulties). The
supplemental BR23 questionnaire comprises 23 items
grouped into four functioning (body image, sexual
functioning, sexual enjoyment, future perspective) and
four symptom (systemic side-effects, breast symptoms,
arm symptoms, upset by hair loss symptoms) scales [22].
Items were scaled and scored according to the EORTC
Scoring Manual [23]. Most items are answered based on
a four-point scale ranging from 1 (not at all) to 4 (very
much). The two items assessing global health and
overall quality of life are responded to in seven
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Raw scores were transformed to a linear scale ranging
from 0 to 100. For scores measuring function, a higher
score represents a ‘better’ level of functioning, while for
scores measuring symptoms, a higher score represents
‘worse’ level of symptoms.2.3. Statistical considerations
The sample size was based on the primary study end-
point, OS. Patients were evaluable for the HRQoL
analysis if they completed their baseline and at least one
follow-up questionnaire. At each assessment point,
summary statistics of absolute scores and changes from
baseline were calculated by treatment group, including
best and worst changes, for each subscale. Change from
baseline over time was analysed by repeated measures
linear mixed effects (Mixed effect Model Repeat Mea-
surement or MMRM) [24,25] for domains/symptoms
with multiple questions and generalised linear mixed
models (GLMM) for domains/symptoms with a single
question [26]. In the MMRM analysis, change from
baseline was the dependent variable and treatment
group, visit, and treatment group-by-visit interaction,
the three predefined stratification factors (geographic
region, prior eribulin, and receptor status) as fixed ef-
fects, and baseline value were the covariates. Minimal
Important Difference (MID) thresholds, using a
threshold of 5 points, were used to categorise patients
as improved (þ5), stable (>5 to <þ5), or worsened
(5). Treatment comparison of the proportion of pa-
tients in each category was conducted using a propor-
tional odds model and odds ratios were calculated with
QoL status as the dependent variable coded as 3, 2 and
1 for improved, stable, and worsened respectively; the
independent variables included treatment arm,
geographic region, prior use of eribulin, and receptor
status. To meet criteria for improved or worsened, a
subsequent confirmatory assessment at  4 weeks was
required. Chi-square test was used to report P-values
from a proportional odds model. Questionnaire
completion rates were calculated as a percentage of
eligible subjects who completed a questionnaire at each
scheduled time point per the study protocol for each
treatment group.3. Results
3.1. Patient characteristics
Baseline demographic and disease characteristics of the
852 patients (etirinotecan pegol, n Z 429; TPC,
n Z 423; Fig. 1) randomised were generally well
balanced between treatment groups as previously re-
ported [16] (Table 1). The median age was 55 years, and
median time since diagnosis of locally recurrent ormetastatic disease was 2.5 years. Almost all patients had
a good performance status (ECOG 0-1), although a
slightly higher proportion of those in the etirinotecan
pegol arm had an ECOG PS of 0 than in the TPC arm
(41% versus 32%, respectively). Over two-thirds of the
population in both treatment arms had hormone re-
ceptor (ER or PR) positive and approximately 28% had
triple-negative breast cancer (TNBC) disease. The most
common sites of metastatic disease were bone (57%),
liver (54%) and lung (38%); sixty-seven patients (8%)
had a history of brain metastases. The median number
of prior regimens for metastatic disease in each treat-
ment group was three; 38 [9%] patients randomised to
etirinotecan pegol had received five or more prior regi-
mens in the metastatic setting versus 20 [5%] patients in
the TPC arm.
Patients in both treatment groups received a median
of three treatment cycles on protocol. The most
commonly administered drug in the TPC arm was eri-
bulin (40%), followed by vinorelbine (23%), gemcitabine
(18%), nab-paclitaxel (8%), paclitaxel (4%), ixabepilone
(4%) and docetaxel (3%). Baseline HRQoL scores were
comparable between the treatment arms (Table 1); of
note, mean GHS and physical functioning scores were
similar between the two arms. Mean GHS scores were
61.4 (standard deviation [S.D.] Z 21.76) and 58.0
(S.D. Z 20.43) for etirinotecan pegol and TPC,
respectively; mean physical functioning scores were 74.5
(S.D. Z 19.72) and 72.3 (S.D. Z 19.74), respectively.
3.2. HRQoL compliance results
Almost all randomised patients completed the baseline
HRQoL questionnaire in both the etirinotecan pegol
(98%, 422/429) and TPC arms (97%, 409/423) (Table 2);
and most (86%, 733/852) completed at least one post-
baseline HRQoL questionnaire (etirinotecan pegol: 378
[88%], TPC: 355 [84%]). Compliance for completion of
questionnaires at each visit during the treatment period
was 95% (range 87%e96%). As expected, the number of
patients completing the questionnaire decreased over
time, and by week 32, 16% (69/429) patients in the
etirinotecan arm and 14% (59/423) patients in the TPC
arm completed the questionnaire. By week 40, less than
10% of patients completed the questionnaire [9% (79/
852) overall, 11% (48/429) patients in the etirinotecan
arm and 7% (31/423) patients in the TPC arm], sup-
porting a primary analysis in which data were assessed
up to week 32 as preplanned in the protocol.
3.3. Global health status and functioning
The primary assessment of HRQoL occurred up to
32 weeks following randomisation. Findings from the
GHS and five functioning domains (physical, role,
emotional, cognitive and social) of the EORTC QLQ C-
30 showed that HRQoL deteriorated slightly in both
Fig. 1. Consort diagram: BEACON trial.
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each assessment time consistently favoured patients in
the etirinotecan pegol arm up to week 32 and became
more marked over time up to that point. Fig. 2A and B
shows GHS and physical functioning mean symptom
scores over time. At week 32, using MMRM analysis,
the mean difference in GHS favouring patients in the
etirinotecan pegol arm was 8.2 points. The individual
functioning domains generally favoured patients in the
etirinotecan pegol arm: physical by 5.7 points, role by
2.1 points, emotional by 3.9 points and cognitive by 5.1
points but social by 0.5 points. A longitudinal analysis
of the MMRM for the change from baseline up to32 weeks showed that etirinotecan pegol was statistically
superior in its effect on GHS and the physical func-
tioning domain (Fig. 3). There was also numerical su-
periority favouring patients in the etirinotecan pegol
arm in the other functional domains. Similar trends were
also observed in the four scales (body image, sexual
functioning, sexual enjoyment, and future perspective)
with the BR23. At the time of disease progression,
analysis of the GHS and physical functioning domains
showed a decline in HRQoL for patients in both arms,
although this was less pronounced for those in the
etirinotecan pegol arm; the mean change from baseline
was 7.97 and 9.83 in GHS and physical functioning,
Table 1
Baseline characteristics and health-related quality of life in the intent-
to-treat population of the BEACON trial.
Characteristic Etirinotecan
pegol (n Z 429)
TPC
(n Z 423)
Age (years) 55 (28e84) 55 (32e80)
ECOG PS
0 175 (41%) 134 (32%)
1 252 (59%) 285 (67%)
2 2 (<1%) 4 (<1%)
Time since initial breast cancer
diagnosis (years)
5.8 (0.6e29.3) 5.4 (0.8e31.9)
Time since diagnosis of locally
recurrent or metastatic
disease (years)
2.5 (0.3e19.7) 2.5 (0.2e22.9)
Stage IV disease at diagnosis 70 (16%) 75 (18%)
Current breast cancer status
Locally recurrent 4 (<1%) 8 (2%)
Metastatic 425 (99%) 415 (98%)
Visceral disease at enrolment 319 (74%) 324 (77%)
History of brain metastases 36 (8%) 31 (7%)
Metastatic sites at enrolment
Brain 19 (4%) 18 (4%)
Liver 229 (53%) 227 (54%)
Lung 155 (36%) 168 (40%)
Bone 246 (57%) 243 (57%)
Hormone receptor status (ER or PR)
Positive 295 (69%) 290 (69%)
Negative 133 (31%) 133 (31%)
Unknown 1 (<1%) 0
HER2 statusa
Positive 30 (7%) 32 (8%)
Negative 395 (92%) 387 (91%)
Unknown 4 (<1%) 4 (<1%)
Triple-negative disease 119 (28%) 117 (28%)
Prior anthracycline 410 (96%) 406 (96%)
Anthracycline refractoryb 58 (14%) 57 (13%)
Prior taxane 429 (100%) 423 (100%)
Taxane refractoryb 178 (42%) 157 (37%)
Prior capecitabine 429 (100%) 423 (100%)
Capecitabine refractoryb 306 (71%) 315 (74%)
Prior eribulin 71 (17%) 72 (17%)
Number of prior regimens for
locally recurrent or
metastatic disease (range)
3 (1e6) 3 (1e6)
1c 1 (<1%) 2 (<1%)
2 122 (28%) 120 (28%)
3 147 (34%) 161 (38%)
4 114 (27%) 118 (28%)
5 40 (9%) 20 (5%)
6þc 5 (1%) 2 (<1%)
EORTC QLQ-C30 GHS and
functioning scores,d mean
(S.D.)
n Z 378 n Z 355
Global health status 61.4 (21.76) 58.0 (20.43)
Physical functioning 74.5 (19.72) 72.3 (19.74)
Role functioning 71.8 (26.81) 67.3 (26.93)
Emotional functioning 72.4 (21.86) 71.9 (20.06)
Cognitive functioning 82.5 (18.70) 81.2 (19.04)
Social functioning 73.0 (26.69) 71.0 (25.06)
EORTC QLQ-C30 symptom scoresd, mean (S.D.)
Fatigue 46.0 (25.04) 48.3 (23.75)
Nausea and vomiting 8.6 (13.39) 9.9 (16.17)
Pain 32.3 (27.20) 35.3 (28.01)
Dyspnoea 24.5 (27.44) 23.6 (26.20)
Insomnia 29.3 (28.94) 31.5 (27.11)
Appetite loss 24.3 (27.55) 26.6 (27.89)
Table 1 (continued )
Characteristic Etirinotecan
pegol (n Z 429)
TPC
(n Z 423)
Constipation 24.3 (27.55) 26.6 (27.89)
Diarrhoea 6.3 (13.64) 5.6 (11.14)
Financial difficulties 26.4 (31.29) 21.9 (28.95)
EORTC QLQ-BR23 scores,d mean (S.D.)
Body image 69.5 (28.94) 69.9 (27.91)
Sexual functioning 14.1 (19.24) 13.3 (18.91)
Sexual enjoyment 36.1 (29.25) 34.2 (30.77)
Future perspective 36.1 (29.25) 34.2 (30.77)
EORTC QLQ-BR23 symptom scores,d mean (S.D.)
Systemic side-effects 21.9 (16.37) 22.3 (15.15)
Breast symptoms 15.3 (21.55) 15.8 (20.79)
Arm symptoms 20.8 (23.40) 22.2 (22.75)
Upset about hair loss
symptoms
33.2 (34.15) 30.5 (33.29)
Data are n (%) or median (range) unless otherwise designated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group;
EORTC QLQ-BR23, European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire Breast Cancer
Module; EORTC QLQ-C30, European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire Core 30 items; ER,
oestrogen receptor; HER2, human epidermal growth factor receptor
type 2; PR, progesterone receptor; S.D., standard deviation; TPC,
treatment of physician’s choice.
a HER2 status was determined regardless of hormone receptor
status.
b Refractory disease was defined as disease progression while
receiving therapy in the metastatic setting within 8 weeks of the last
dose of the last regimen.
c These patients were entered into the protocol in violation of the
entry criteria which stipulated that patients must have received be-
tween 2 and 5 regimens for locally recurrent or metastatic disease.
d Raw scores were transformed to a linear scale ranging from 0 to
100, with a higher score representing a higher level of functioning or
higher level of symptoms.
Table 2
Health-related quality of life EORTC QLQ-C30 global health status
questionnaire.
Assessment Etirinotecan Pegol
(n Z 429)
TPC
(n Z 423)
Total
(n Z 852)
Baseline 422 (98%) 409 (97%) 831 (98%)
Completed  1 378 (88%) 355 (84%) 733 (86%)
Week 8 337 (78%) 311 (73%) 648 (76%)
Week 16 181 (42%) 159 (38%) 340 (40%)
Week 24 116 (27%) 90 (21%) 206 (24%)
Week 32 69 (16%) 59 (14%) 128 (15%)
Week 40 48 (11%) 31 (7%) 79 (9%)
Week 48 29 (7%) 19 (5%) 48 (6%)
Week 56 26 (6%) 15 (4%) 41 (5%)
Abbreviations: EORTC QLQ-C30, European Organisation for
Research and Treatment of Cancer Quality of Life Questionnaire Core
30 items; TPC, treatment of physician’s choice.
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and 10.83 and 11.74, respectively for those in the
TPC arm.
Fig. 4A shows the percentage of patients with a
change from baseline of 5 points, either improved (5)
Fig. 2. Global health status and physical functioning mean symptom scores over time. Abbreviations: EORTC QLQ-C30, European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; EP, etirinotecan pegol; ITT, intent-to-
treat; LS mean, least-squares mean; MMRM, Mixed effect Model Repeat Measurement; TPC, treatment of physician’s choice.
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functioning scales. All categories were similar between
the treatment arms for GHS and physical functioning,
although numerically more patients had improved
physical functioning on the etirinotecan arm. Only a
small proportion of patients had change from baseline
5 points in the same direction on at least two consec-
utive assessments, and MID analysis of GHS and all
functioning domains did not show statistically signifi-
cant differences between the two treatment arms.
Post hoc analysis of change in GHS and the func-
tioning domains following the onset of grade 3 or higher
AEs showed that QoL deteriorated significantly. Over-
all, patients without any grade 3 or higher AE consis-
tently had better GHS and scores in all five functioning
domains of the QLQ C-30 than those who had grade 3
AEs (all with P-value <0.05 by MMRM analysis).
3.4. Symptom scales
Ten symptom scales were collected: six single-item
symptom scales (dyspnoea, insomnia, appetite loss,
constipation, diarrhoea, and financial difficulties) in the
QLQ C-30 and four symptom scales (systemic therapyside-effects, breast symptoms, arm symptoms, upset by
hair loss symptoms) in BR23. Symptoms scales (Fig. 4B)
closely matched the AE profiles previously reported for
each group [16] with a higher percentage of patients in
the etirinotecan pegol group having worsening of
gastrointestinal symptoms, i.e. nausea and vomiting
(18% versus 9% with TPC, OR Z 2.3), appetite loss
(18% versus 12%, ORZ 1.5), and diarrhoea (14% versus
5%, OR Z 1.9); by contrast, a greater percentage of
patients in the TPC group had worsening of dyspnoea
(12% versus 8% with EP, OR Z 0.6) and systemic side-
effects (23% versus 14%, OR Z 0.6). A higher propor-
tion of patients in the etirinotecan arm had improve-
ment in dyspnoea (14% versus 8% in TPC arm,
respectively).
3.5. Brain metastases subgroup
Favorable HRQoL with etirinotecan pegol was also
observed in the subgroup of patients with stable brain
metastases at baseline. Although the sample size
(n Z 67) was small, the point estimate of the difference
between the treatment groups favouring etirinotecan
pegol was greater than 10 points for GHS (15.0), role
Fig. 3.Mean change from baseline of the EORTC QLQ-C30 and EORTC QLQ-BR23 scales over 32 weeks using MMRM. Abbreviations:
EORTC QLQ-BR23, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer
Module; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items;
EP, etirinotecan pegol; LS mean, least squares mean; MMRM, Mixed effect Model Repeat Measurement; SE, standard error; TPC,
treatment of physician’s choice.
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greater than 5 points for the other functioning domains
(Table 3). Etirinotecan pegol was associated with worse
symptoms of diarrhoea, nausea and vomiting, and
appetite loss; by contrast, patients in the TPC treatment
arm had worse symptoms of dyspnoea, fatigue, and
constipation. The systemic side-effects symptom scale
was improved 13.5 points in patients treated with etir-
inotecan pegol compared with TPC.4. Discussion
The current analysis shows that in the BEACON trial,
etirinotecan pegol treatment was associated with im-
provements in HRQoL as measured by the well-
established EORTC instruments, QLQ-C30 and QLQ-
BR23. Improvements in both GHS and physical func-
tioning reached statistical significance over a 32-week
time period as estimated using an MMRM- test. The
pattern was less consistent after week 32, most likely a
function of the sample size decreasing consistently over
time with less than 10% of patients providing an
assessment on or after week 40. There was a clear dif-
ference in quality of life according to the presence (orabsence) of grade 3 or higher AEs; patients without any
grade 3 adverse events consistently had better HRQoL
as measured by GHS and all five functioning domains of
the EORTC QLQ-C30 questionnaire regardless of
treatment arm.
Two toxicities are worthy of additional discussion.
First, dyspnoea (frequently a symptom of progression in
patients with advanced breast cancer) improved in pa-
tients receiving etirinotecan pegol but deteriorated in
those receiving TPC; this may reflect more effective
treatment of lung metastases, which were present at
baseline in 36% and 40% of patients in the etirinotecan
pegol and TPC arms, respectively [16]. Alopecia is a
potentially troubling toxicity for patients with advanced
cancer. Although there was no statistical difference in
the change from baseline in patients reporting being
upset by hair loss, the overall incidence of alopecia in the
etirinotecan pegol arm was less than half that in the TPC
arm (10% and 23%, respectively) [16]. Finally, more
patients withdrew from the etirinotecan pegol arm than
the TPC arm due to adverse events (47 and 27, respec-
tively), even though the incidence of grade 3 or worse
events was significantly lower among patients treated
with etirinotecan pegol (204 [48%] versus 256 [63%],
respectively; odds ratio 0$54 [95% CI 0.41e0.71];
Fig. 4. Summary of status of EORTC QLQ-C30 and EORTC QLQ-BR23 symptom scales using 5-point change threshold. Abbreviations:
EORTC QLQ-BR23, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer
Module; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items;
EP, etirinotecan pegol; TPC, treatment of physician’s choice. Note: A threshold of 5 score points of change from baseline in the linear
transformed score was used to classify status as Improved (þ5), Stable (>5 to <5), or Worsened (5). The first post-baseline status
meeting Improved or Worsened with a subsequent confirmatory assessment in 4 weeks or later is counted. Proportional odds model was
used to test the difference in proportion between treatment groups for each scale. The QoL status was the dependent variable and coded as
3, 2, and 1 for Improved, Stable, and Worsened, respectively. The independent variables will include treatment arm, geographic region,
prior use of eribulin and receptor status.
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etirinotecan pegol arm may in part be a consequence of
strict dosing guidelines reflecting its long elimination
half-life, including mandatory cessation of dosing for
repeated grade 2 diarrhoea and grade 2 neutropenia,
which did not apply to the TPC arm.
As previously reported BEACON did not achieve its
primary end-point; although there was a 2.1-month
improvement in survival for patients treated with etir-
inotecan pegol compared to those receiving TPC that
emerged early and persisted, this difference did not
reach statistical significance (median 12.4 months versus
10.3 months for TPC; HR 0.87, 95% CI 0.75e1.02;
P Z 0.084) [16]. The trend for improvement in survival
with etirinotecan pegol was noted across all subgroups.
Importantly, in the preplanned subgroup of patientswith stable brain metastases at study entry, etirinotecan
pegol treatment was associated with a statistically sig-
nificant 5.2-month improvement in median overall sur-
vival (10.0 months compared to 4.8 months in the TPC
arm, n Z 67, HR 0.51, P < 0.01). Similar results be-
tween treatment groups were observed for progression-
free survival (PFS) (HR Z 0.93, 95% CI 0.80e1.1) but
more than twice as many patients were withdrawn from
the TPC arm (55 compared to 27 patients) due to phy-
sician’s decision; this includes patients withdrawn from
the study due to clinical progression without radio-
graphic progression. The ORR was very similar for the
etirinotecan pegol and TPC arms (16% and 17%,
respectively).
Based on these data, and a previous randomised
phase II clinical trial [27], etirinotecan pegol is an active
Table 3
Health-related quality of life in brain metastases at baseline subgroup.
Domain Treatment
Difference (SE)a
95% CIa
EORTC QLQ-C30 global health status and functional domainsb
Global health status 15.0 (7.76) 0.57, 30.51
Physical functioning 8.2 (6.62) 5.06, 21.45
Role functioning 11.6 (8.86) 6.19, 29.44
Emotional functioning 7.1 (6.22) 5.38, 19.52
Cognitive functioning 12.1 (6.13) 0.27, 24.4
Social functioning scale 8 (7.54) 7.12, 23.21
EORTC QLQ-C30 and BR23 symptom scalesc
Fatigue symptom 5.4 (6.62) 18.7, 7.89
Nausea and vomiting symptom 13.7 (8.38) 3.08, 30.52
Pain symptom 15.9 (8.47) 32.82, 1.09
Dyspnoea symptom 4.9 (6.9) 18.85, 9.12
Appetite loss symptom 5.4 (9.1) 12.81, 23.7
Constipation symptom 11.2 (8.21) 27.67, 5.28
Diarrhoea symptom 5 (7.97) 10.97, 21
Systemic side-effects mptom 13.5 (4.54) 22.55, 4.37
Abbreviations: CI, confidence interval; EORTC QLQ-BR23, Euro-
pean Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire Breast Cancer Module; EORTC QLQ-C30, Euro-
pean Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 items; MMRM, Mixed effect Model
Repeat Measurement; TPC, treatment of physician’s choice; SE,
standard error.
a Difference in mean change from baseline over 32 weeks using
MMRM.
b Positive value for functioning scales favours etirinotecan pegol and
negative value favours TPC.
c Negative value for symptoms favours etirinotecan pegol and pos-
itive value favours TPC.
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breast cancer. Recognisable advantages of etirinotecan
pegol are its non-cross-resistant mechanism of action
and non-overlapping toxicity profile, specifically the
lack of significant myelosuppression or neuropathy that
frequently affect patients with heavily pre-treated dis-
ease. Importantly, the BEACON trial demonstrated that
etirinotecan pegol was associated with significantly
fewer grade 3 or higher adverse events compared to TPC
(48% and 63%, respectively; P < 0.001). The improve-
ment in many aspects of HRQoL, together with the
tolerability and efficacy findings from the BEACON
trial, reinforces that etirinotecan pegol is a potentially
important new agent in the treatment of patients with
metastatic breast cancer. Notably, although gastroin-
testinal AEs and symptoms were more pronounced with
etirinotecan pegol, overall HRQoL, as reflected by
GHS, was better in those patients suggesting that the
benefits of a more effective treatment may outweigh
treatment toxicities.
In the management of women with advanced breast
cancer, where clinical outcomes with various treatment
options may be similar and improvements modest,
HRQoL provides crucial information beyond that of
standard efficacy outcomes, especially where no single
standard of care exists. There remains a need for new
agents to treat advanced breast cancer that shouldpreferably belong to a novel class, or have a novel mech-
anism of action, and impact survival while maintaining or
improving QoL, being well-tolerated, and supported by a
sound body of evidence. Based on the data reported to
date, etirinotecanpegol is a promising agentwhose efficacy
and favourable safety profile are reflected in improved
HRQoL for patients with advanced breast cancer
compared to cytotoxics currently used in this setting. In
June 2016, Nektar Therapeutics submitted a market-
ing authorization application (MAA) for conditional
approval of Onzeald (etirinotecan pegol) in Europe for
the treatmentof adult patientswithbreast cancer andbrain
metastases. A decision on the conditional approval from
the Committee for Medicinal Products for Human Use
(CHMP) is expected in 2017.
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